How to Build a Strong Strategy for Biosimilar Medicine Development and Approach Bioequivalence Effic

Richard Peck, Director for Regulatory Affair at Finox, sums up the main challenges in developing biosimilar medicines, including cost-cutting pressures and the need to take on board regulatory changes and technology shifts. The interview drills down on Regulatory Authority requirements for the demonstration of bioequivalence and how this can prove an obstacle to developing biosimilars. Exploring the other side of the coin, the interview takes a look at the key opportunities available today in developing biosimilar medicines.